Yabao Pharmaceutical (Shanghai Securities: 600351) announced on November 21, 2014 that it would cooperate with MRC Technology (MRCT) to research, develop and commercialize an innovative drug for neurodegenerative diseases - kinase targeted innovative drug for the treatment of Parkinson's disease.
Under the terms of the agreement, Albo has the right to research, develop and sell the Chinese mainland, Taiwan and Hongkong, while MRCT reserves the rights of all other markets. The financial terms were not disclosed.
Dr. Wang Peng, President of R & D of Yabao pharmaceutical, said: "MRCT is a British research institution and has been committed to improving the quality of life of patients through medical discovery. Yabao is very happy to cooperate with MRCT. Taking the opportunity of cooperation, Yabao has explored and innovated and participated in the new research battlefield of innovative drug development, which is further evidence of Yabao pharmaceutical's use of science and technology to treat serious diseases."
Michael Dalrymple, director of business development at MRCT, said: "Parkinson's disease is a debilitating and devastating disease. We are glad to combine our expertise with a large number of resources brought by Yabao pharmaceutical to jointly develop groundbreaking new drugs in the early stage of drug discovery and innovation. Both of us hope to do more for patients, not only bring innovative treatment to them, but also improve their quality of life."
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) As a Chinese pharmaceutical enterprise, Yabao has perfect capabilities in drug development, production and commercialization in China. Recently, Yabao has adjusted its strategic development direction and aimed at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities, and the production of preparations and APIs meets the quality management of drug production CGMP requirements and passed the inspection of FDA and EU drug regulatory authorities respectively.
About MRC Technology
MRC technology is an independent science and technology transfer charity in the field of life sciences. It provides professional services for scientific research institutes, charities, biological and pharmaceutical companies around the world. These services include IP management and R & D services for diagnostic reagents, small molecules and therapeutic antibodies. MRC technology is committed to building a communication bridge between basic research and commercialization to help early R & D The project is promoted to clinical application.
请将简历发送至：